Key Takeaways
- • Garrett Smith, a UC San Diego bioengineering PhD (2012) with extensive experience scaling medtech companies through FDA approval and corporate venture roles at Johnson & Johnson Innovation and MedeonBIO, has launched ReefHaven Ventures as founding managing partner, targeting early-stage San Diego medical technology startups.
- • ReefHaven Ventures has already deployed capital into three UC San Diego-affiliated medtech companies—KatoMed, Acurion, and Dragon Vascular—with plans for more than two dozen additional investments in San Diego medtech over the coming years, focusing on the convergence of medical technology, artificial intelligence, and robotics.
- • The fund is explicitly designed to strengthen San Diego's early-stage venture ecosystem, which Smith argues lacks sufficient institutional support compared to the Bay Area, despite UC San Diego ranking in the top 10 nationally for startup creation.
- • ReefHaven Ventures operates in partnership with UC San Diego, leveraging institutional resources and the university's MedTech Accelerator to identify and support portfolio companies across students, faculty, clinicians, and alumni-founded ventures.
Summary
ReefHaven Ventures, a newly launched early-stage venture capital fund, marks a strategic effort to address a structural gap in San Diego's medical technology funding landscape. Founded by Garrett Smith, a UC San Diego bioengineering alumnus with a doctoral degree from 2012, the fund represents a consolidation of nearly two decades of healthcare innovation experience across multiple stages of company development and corporate infrastructure.
Smith's operational background spans the full medtech innovation cycle. As a founder during his doctoral studies, he has subsequently guided multiple technologies through FDA regulatory approval, executed successful exits as a company leader, directed innovation partnerships at Johnson & Johnson Innovation, and managed a corporate venture capital fund at MedeonBIO. This breadth of experience positions him to identify commercially viable technologies and mentor early-stage founders through capital-intensive development and regulatory pathways characteristic of the medtech sector.
The fund's strategic thesis centers on addressing what Smith characterizes as a regional deficiency in early-stage capital deployment. "UC San Diego innovation rivals anything out of the Bay Area," Smith stated, "but San Diego lacks the same supporting ecosystem, especially when it comes to early stage investors." UC San Diego's Associate Vice Chancellor for Innovation and Commercialization Paul Roben corroborated the region's research strength, noting the university "consistently ranks in the top 10 universities nationally for startup creation." ReefHaven's partnership with UC San Diego's institutional infrastructure, including its MedTech Accelerator, provides systematic access to deal flow across institutional research, faculty entrepreneurship, student ventures, and alumni networks.
Initial deployment demonstrates focused sector conviction. Three portfolio companies—KatoMed, Acurion, and Dragon Vascular—have already received investment, with KatoMed additionally supported by Kyocera Ventures. The fund's investment thesis emphasizes the convergence of medical devices, artificial intelligence, and robotics, sectors where San Diego's research capabilities and corporate medtech presence create competitive advantages. With plans for more than two dozen additional investments planned over the coming years, ReefHaven Ventures positions itself as an anchor institution for San Diego's medtech ecosystem, targeting the capital gap between angel funding and institutional venture rounds that has historically disadvantaged the region relative to established venture hubs.
Smith's operational background spans the full medtech innovation cycle. As a founder during his doctoral studies, he has subsequently guided multiple technologies through FDA regulatory approval, executed successful exits as a company leader, directed innovation partnerships at Johnson & Johnson Innovation, and managed a corporate venture capital fund at MedeonBIO. This breadth of experience positions him to identify commercially viable technologies and mentor early-stage founders through capital-intensive development and regulatory pathways characteristic of the medtech sector.
The fund's strategic thesis centers on addressing what Smith characterizes as a regional deficiency in early-stage capital deployment. "UC San Diego innovation rivals anything out of the Bay Area," Smith stated, "but San Diego lacks the same supporting ecosystem, especially when it comes to early stage investors." UC San Diego's Associate Vice Chancellor for Innovation and Commercialization Paul Roben corroborated the region's research strength, noting the university "consistently ranks in the top 10 universities nationally for startup creation." ReefHaven's partnership with UC San Diego's institutional infrastructure, including its MedTech Accelerator, provides systematic access to deal flow across institutional research, faculty entrepreneurship, student ventures, and alumni networks.
Initial deployment demonstrates focused sector conviction. Three portfolio companies—KatoMed, Acurion, and Dragon Vascular—have already received investment, with KatoMed additionally supported by Kyocera Ventures. The fund's investment thesis emphasizes the convergence of medical devices, artificial intelligence, and robotics, sectors where San Diego's research capabilities and corporate medtech presence create competitive advantages. With plans for more than two dozen additional investments planned over the coming years, ReefHaven Ventures positions itself as an anchor institution for San Diego's medtech ecosystem, targeting the capital gap between angel funding and institutional venture rounds that has historically disadvantaged the region relative to established venture hubs.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.